Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?

Oct 26 2016

• By Mandy Jackson

Related Content

Lilly's Lung Cancer Drug Portrazza OK'd

Nov 25 2015

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Oct 19 2016

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

From Solanezumab To Solithromycin: What To Watch For In Q4

Oct 11 2016

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

Oct 10 2016

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

Sep 22 2016

10 Things You Want To Know About Alzheimer's Drug Research

May 13 2016

Lilly Executes Growth Strategy As New Products Drive Sales Gains

Apr 27 2016

Lilly's Leap Tests Investors' Faith In Solanezumab

Mar 16 2016

FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx

Mar 23 2016

Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance

Jul 27 2016

Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO

Jul 28 2016

Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Sep 13 2016

Remicade Most Cost-Effective Biologic For Psoriasis In ICER Analysis

Sep 30 2016

Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence

Aug 31 2016

Related Companies

Eli Lilly and Company

AstraZeneca PLC

Roche Holding AG

Genentech, Inc.

Merck & Co., Inc.

Additional Topics

Sales & Earnings Research & Development Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window